Physician profile
Samir Ashfaq
NPI 1588009815
$5,513.48
in general payments reported to CMS, 2019-2025
30 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.09 · 2020: $136 · 2021: $883 · 2022: $951 · 2023: $1,247 · 2024: $1,247 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,513.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,176.89 | 2021-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,064.69 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Merck Sharp & Dohme LLC | $416.87 | 2020-2024 | Dificid, Zerbaxa, Recarbrio |
| Celgene Corporation | $362.36 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $307.57 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $251.86 | 2021-2023 | Sucraid |
| Janssen Biotech, INC. | $237.76 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $205.98 | 2021-2023 | |
| Braintree Laboratories, INC. | $197.26 | 2019-2023 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $191.88 | 2023-2024 | Linzess |
| Madrigal Pharmaceuticals | $158.51 | 2024-2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $128.11 | 2024-2025 | Voquezna |
| Vivus LLC | $105.84 | 2024-2025 | Pancreaze, Qsymia |
| Ardelyx, INC. | $93.41 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $76.68 | 2024 | Omvoh |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $64.34 | 2024-2025 | Zenpep, Vowst |
| Medtronic, INC. | $62.14 | 2025 | Manoscan |
| Ferring Pharmaceuticals INC. | $61.94 | 2021-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $51.33 | 2024-2025 | Dupixent |
| Gilead Sciences, INC. | $41.75 | 2022-2023 | |
| Evoke Pharma, INC. | $39.47 | 2023-2024 | Gimoti |
| Pfizer INC. | $37.94 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $29.54 | 2023 | Zeposia |
| Genzyme Corporation | $27.07 | 2025 | |
| Ambu INC. | $23.50 | 2021 | |
| Biocon Biologics INC | $20.83 | 2025 | Hulio |
| Alfasigma USA, INC. | $19.71 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $19.68 | 2023 | Andexxa |
| Alcresta Therapeutics, INC. | $19.59 | 2023 | Relizorb |
| Intercept Pharmaceuticals, INC. | $18.98 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Ashfaq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.